Surrogate Endpoint, Safety Questions May Be Too Much For Waylivra To Overcome At US FDA Panel

 
• By Michael Cipriano
  
Generate a summary of this article
Listen to this article
Beta

Akcea Therapeutics' familial chylomicronemia syndrome drug will be faced with questions about its surrogate endpoint and a thrombocytopenia safety signal.

A surrogate endpoint with uncertain clinical benefits combined with a thrombocytopenia safety signal are among the several factors that could derail the approval prospects of Akcea Therapeutics Inc.'s Waylivra (volanesorsen), which heads for an assessment by the US FDA's Endocrinologic and Metabolic Drugs Advisory Committee May 10 for the treatment of familial chylomicronemia syndrome (FCS).

A modified phosphorothioate antisense oligonucleotide (ASO), Waylivra would be the first pharmacotherapy if approved for the rare genetic syndrome, which...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered. 

EU Filings Tracker TEST

New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.

US FDA Adcomm Reform Ideas: Neutral Facilitator As Chair, Public Hearing Lottery Process Tweaks

 
• By Sue Sutter

Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.

More from Regulatory Trackers

Ocaliva Confirmatory Trial Failed To Verify Benefit In Primary Biliary Cholangitis, US FDA Says

 
• By Sue Sutter

A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.  

Global Pharma Guidance Tracker – August 2024

 
• By Vibha Sharma

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.